Form 4: Apogee Therapeutics Chief Medical Officer Executes Stock Transactions

Apogee Therapeutics' Chief Medical Officer, Carl Dambkowski, exercised stock options and sold shares under a pre-arranged trading plan.

Summary

• Carl Dambkowski, Chief Medical Officer of Apogee Therapeutics, executed several transactions involving the company's stock on January 2, 2025.
• He acquired 1,360 shares of common stock through the exercise of stock options at a price of $22.86 per share.
• He also sold a total of 4,085 shares of common stock in multiple transactions at weighted average prices of $46.42, $47.21 and $47.92 per share.
• These transactions were conducted under a Rule 10b5-1 trading plan adopted on August 21, 2024.
• Following these transactions, Mr. Dambkowski beneficially owns 255,348 shares of Apogee Therapeutics common stock.

Sentiment

Score: 6

Explanation: The document reflects standard executive stock transactions under a pre-arranged plan. While the sales might cause minor concern, the overall sentiment is neutral to slightly positive due to the option exercise.

Positives

• The exercise of stock options indicates confidence in the company's future prospects by the Chief Medical Officer.
• The sales were executed at prices significantly higher than the option exercise price, suggesting a positive market valuation.

Negatives

• The sale of shares by a key executive could be interpreted negatively by some investors, although it is part of a pre-arranged plan.

Risks

• Executive stock sales, even under a pre-arranged plan, can sometimes create short-term price volatility.
• The market may react negatively to insider selling, regardless of the reason.

Industry Context

This type of transaction is common for executives of publicly traded companies, especially those with stock-based compensation. The use of a Rule 10b5-1 plan is a standard practice to avoid accusations of insider trading.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a common practice among executives at publicly traded companies, such as those in the biotechnology sector like Regeneron Pharmaceuticals or Vertex Pharmaceuticals.
• The vesting schedule of the options, with monthly installments over several years, is also typical for executive compensation packages in the industry.
• The sale of shares at a price significantly higher than the exercise price is a common outcome when a company's stock performs well, similar to what might be seen with executives at companies like Moderna or BioNTech.

Stakeholder Impact

• Shareholders may react to the stock sales, but the pre-arranged nature of the transactions should mitigate any negative impact.
• Employees may view the stock option exercise as a positive sign of the company's prospects.

Key Dates

Keywords

Apogee Therapeutics, Carl Dambkowski, stock options, insider trading, Rule 10b5-1, stock sales, executive compensation, APGE